Innovent Biologics

Innovent Biologics is a publicly listed Chinese biopharmaceutical company headquartered in Suzhou, Jiangsu. Founded in 2011 by Yu Dechao, the company initially concentrated on the discovery and development of monoclonal antibodies, an area that has become central to modern treatment of cancer, autoimmune disorders, and other serious diseases. Innovent has since expanded into a broader biotechnology platform covering research, clinical development, manufacturing, regulatory affairs, and commercial distribution. The company was established during a period in which China’s pharmaceutical sector was moving from a predominantly generic-drug model toward biologics and internally developed innovative medicines. Innovent’s strategy combined in-house research and development with external financing and partnerships. Early financial backing came from venture investors and strategic institutions, including Eli Lilly and Company, Fidelity Investments, China Life, Hillhouse Capital, and Temasek. These relationships helped support the construction of development and manufacturing capabilities while giving Innovent access to international pharmaceutical expertise and potential commercialization channels. A significant early turning point came in March 2015, when Innovent and Eli Lilly entered an agreement covering the co-development of at least three experimental cancer medicines. The arrangement provided Innovent with an upfront payment and the prospect of additional payments tied to development and commercial achievements. The partnership illustrated Innovent’s dual emphasis on developing medicines for China and establishing commercial links with multinational pharmaceutical companies. Innovent completed its initial public offering on the Hong Kong Stock Exchange in October 2018. The listing provided additional capital for clinical programs, manufacturing infrastructure, and commercialization. Two months later, China approved sintilimab, an anti-PD-1 monoclonal antibody developed by Innovent. Sintilimab became one of the company’s most important products and later formed the basis of a major international licensing arrangement with Eli Lilly. In 2020, Lilly paid an upfront amount for rights outside China and committed additional potential funding linked to development and commercial milestones. The arrangement was subsequently terminated in December 2022 after the United States Food and Drug Administration rejected an application involving sintilimab. Innovent’s portfolio has broadened beyond oncology antibodies. Its activities include biologic therapies and drug candidates in areas such as autoimmune disease and metabolic disorders. In June 2025, China approved mazdutide, a GLP-1 medicine for weight management and diabetes. The approval marked a major expansion into the rapidly developing metabolic-medicine market and was described in the supplied reference material as the first Chinese approval for a domestically developed GLP-1 drug for both weight loss and diabetes. Innovent also partnered with JD Health in connection with distribution of the product. The company’s business model combines product commercialization in China with licensing, co-development, and strategic partnerships for selected assets. In 2025, Sanofi announced an investment in Innovent connected with the joint development of two cancer medicines in China. Later that year, Takeda Pharmaceutical Company announced a much larger collaboration concerning immuno-oncology and antibody-drug-conjugate therapies, including an upfront payment and potential development support. These transactions reflect Innovent’s role as both a domestic commercial biopharmaceutical company and a partner for global pharmaceutical groups seeking access to Chinese innovation and development capabilities. Innovent positions itself around innovation, quality, and improving access to advanced medicines. Its principal business scope includes biologics research and development, clinical testing,…

Innovent Biologics was founded in 2011 by Yu Dechao with an initial emphasis on monoclonal-antibody medicines. Its formation reflected the increasing development of China’s biotechnology sector and the growing importance of biologic therapies in oncology and other serious diseases. Rather than limiting itself to laboratory research, Innovent developed an integrated model spanning discovery, clinical development, manufacturing, regulatory work, and commercialization. The company attracted financial and strategic support from a number of institutional investors, including Eli Lilly and Company, Fidelity Investments, China Life, Hillhouse Capital, and Temasek. Eli Lilly became an especially important partner. In March 2015, the two companies agreed to co-develop at least three experimental cancer medicines. The deal included an upfront payment to Innovent and the possibility of further payments if specified development and commercial milestones were achieved. The agreement helped establish Innovent’s reputation as a Chinese biotechnology company capable of working with major multinational pharmaceutical groups. Innovent went public in October 2018 through an initial public offering on the Hong Kong Stock Exchange. The offering raised capital to support its pipeline and infrastructure. In December of the same year, China approved sintilimab, an anti-PD-1 monoclonal antibody. The product became a major milestone for Innovent and an important part of the company’s oncology strategy. In 2020, Eli Lilly obtained rights outside China to sintilimab through an agreement that included an upfront payment and additional potential funding. The arrangement was intended to support international development and commercialization. In December 2022, Lilly terminated the agreement after the United States Food and Drug Administration rejected an application involving the medicine. The event demonstrated the regulatory and commercial challenges involved in taking an oncology product from the Chinese market into the United States. Innovent subsequently expanded beyond its original oncology-centered identity. Its portfolio and research programs have included autoimmune diseases, metabolic disorders, and additional biologic platforms. In June 2025, mazdutide was approved in China for weight management and diabetes. The approval represented a significant move into GLP-1 medicines and was described in the supplied reference material as the first approval for a Chinese company to market a GLP-1 drug for weight loss and diabetes. Innovent worked with JD Health in relation to distribution. The company also continued to use partnerships to broaden the reach and development resources available to its pipeline. In August 2025, Sanofi announced an investment in Innovent associated with the joint development of two cancer medicines in China. In October 2025, Takeda announced a major agreement involving immuno-oncology and antibody-drug-conjugate therapies, with an upfront payment and a stated aim of accelerating development. These transactions added to Innovent’s international network of pharmaceutical relationships. By the end of the supplied chronology, Innovent had developed from a monoclonal-antibody start-up into an integrated, publicly traded Chinese biopharmaceutical company. Its activities combine domestic commercialization with global licensing and co-development. Oncology remains a defining area, while metabolic medicine has become an increasingly visible growth field. The company’s long-term identity is shaped by its ability to develop biologics in China, obtain regulatory approvals, build manufacturing and commercial capabilities, and collaborate with multinational partners on selected products and technologies.

1. 2025Mazdutide approved in China

   Mazdutide received Chinese approval for weight management and diabetes, expanding Innovent into GLP-1 metabolic medicines.

   Source
2. 2025Sanofi investment and oncology collaboration

   Sanofi announced an investment and a joint development arrangement involving two cancer medicines in China.

   Source
3. 2025Takeda immuno-oncology and antibody-drug-conjugate collaboration

   Takeda announced a large collaboration intended to accelerate development of immuno-oncology and antibody-drug-conjugate therapies.

   Source
4. 2022Termination of Lilly sintilimab agreement

   Eli Lilly terminated the international sintilimab agreement after a United States regulatory rejection.

   Source
5. 2020International sintilimab rights agreement

   Eli Lilly obtained rights outside China to sintilimab under an agreement with upfront and potential milestone-linked payments.

   Source
6. 2018Hong Kong listing

   Innovent completed its initial public offering and began trading on the Hong Kong Stock Exchange.

   Source
7. 2018Sintilimab approved in China

   China approved Innovent’s sintilimab anti-PD-1 monoclonal antibody.

   Source
8. 2015Initial Eli Lilly oncology collaboration

   Innovent and Eli Lilly agreed to co-develop at least three experimental cancer medicines under a milestone-linked arrangement.

   Source
9. 2011Company founded

   Yu Dechao founded Innovent to develop monoclonal-antibody medicines and other biotechnology products.

   Source

An innovation-led Chinese biopharmaceutical company focused on developing and commercializing high-quality biologic and other innovative medicines, with core strengths in oncology and growing activity in autoimmune and metabolic diseases.

• SintilimabAnti-PD-1 monoclonal antibody2018

  Sintilimab is an anti-PD-1 monoclonal antibody and one of Innovent’s principal oncology products. It was approved in China in December 2018. The medicine became the subject of an international development and commercialization agreement with Eli Lilly in 2020, although that agreement was terminated in 2022 after a United States regulatory rejection.

• Bevacizumab biosimilarBiosimilar monoclonal antibody

  Innovent’s portfolio includes a bevacizumab biosimilar, representing the company’s work in oncology biologics and its broader effort to provide high-quality biologic treatments. Bevacizumab-based therapies target vascular endothelial growth factor pathways and are used across several cancer-treatment settings. Specific launch and current regulatory details are not provided in the supplied reference material.

• MazdutideGLP-1 metabolic medicine2025

  Mazdutide is a GLP-1 medicine developed for metabolic indications including weight management and diabetes. China approved the product in June 2025. Its approval marked Innovent’s expansion beyond its historical oncology concentration, and the company partnered with JD Health in connection with distribution.

• 2025Mazdutide distribution partnership with JD Health

  China

  Innovent partnered with JD Health to support distribution of mazdutide following its Chinese approval for weight management and diabetes.

  Outcome. Distribution partnership reported; detailed campaign performance is not provided.

  Source

• 2025Expand into GLP-1 metabolic medicines with mazdutideProduct launch

  Innovent broadened its business beyond its established oncology and antibody focus into the fast-growing metabolic-medicine market.

  What changed. The company obtained Chinese approval for mazdutide for weight management and diabetes and arranged distribution support with JD Health.

  Aftermath. Mazdutide became a prominent part of Innovent’s metabolic portfolio and extended its commercial scope beyond oncology.

  Source
• 2025Partner with Sanofi on two cancer medicinesM&A

  Innovent continued to use strategic partnerships to fund and accelerate development of oncology assets in China.

  What changed. Sanofi announced an investment in Innovent connected with joint development of two cancer drugs in China.

  Aftermath. The arrangement strengthened Innovent’s relationship with a global pharmaceutical company; detailed development outcomes were not provided.

  Sanofi investment. $307.88 million (August 2025)

  Source
• 2025Enter Takeda immuno-oncology and antibody-drug-conjugate collaborationM&A

  Innovent sought to accelerate development of advanced oncology therapies through a large international pharmaceutical partnership.

  What changed. Takeda announced an agreement with Innovent covering immuno-oncology and antibody-drug-conjugate cancer therapies.

  Aftermath. The agreement expanded Innovent’s international collaboration network and provided a platform for further development of selected cancer programs.

  Transaction value and upfront payment. $11.4 billion total deal value, including a $1.2 billion upfront payment (October 2025)

  Source
• 2020Grant Eli Lilly rights outside China to sintilimabM&A

  Innovent pursued international development and commercialization of its lead oncology product through a multinational pharmaceutical partner.

  What changed. Innovent granted Eli Lilly rights outside China to sintilimab under a payment and milestone arrangement.

  Aftermath. Lilly later terminated the agreement in December 2022 after a United States regulatory rejection.

  Upfront and potential milestone payments. $200 million upfront and up to $825 million in potential additional payments (2020 agreement)

  Source
• 2018List on the Hong Kong Stock ExchangeOther

  Innovent required additional capital to fund its pipeline, infrastructure, and commercialization activities.

  What changed. The company completed an initial public offering on the Hong Kong Stock Exchange.

  Aftermath. Innovent became a publicly traded biopharmaceutical company and gained access to public-market financing.

  IPO proceeds. $421 million raised (October 2018)

  Source
• 2015Enter cancer-drug co-development agreement with Eli LillyM&A

  Innovent sought external resources and multinational collaboration to advance a group of experimental oncology medicines.

  What changed. The companies agreed to co-develop at least three experimental cancer drugs under upfront and milestone-linked financial terms.

  Aftermath. The agreement established an important strategic relationship between Innovent and Eli Lilly and preceded the later international licensing arrangement for sintilimab.

  Upfront payment and potential milestone payments. $56 million upfront; more than $400 million in potential additional payments (2015 agreement)

  Source

• 2025China approves Innovent’s mazdutide

  Mazdutide received Chinese approval for weight management and diabetes indications. Innovent also partnered with JD Health in connection with distribution.

  Product launchProduct generation
  Source
• 2025Sanofi announces investment and oncology collaboration with Innovent

  Sanofi announced an investment in Innovent linked to the joint development of two cancer medicines in China.

  M&AOther
  Source
• 2025Takeda announces major collaboration with Innovent

  Takeda announced an agreement with Innovent intended to accelerate the development of immuno-oncology and antibody-drug-conjugate cancer therapies, including an upfront payment.

  M&AOther
  Source
• 2025Innovent announced as a prospective Hang Seng Index constituent

  Reference material stated that Innovent was announced as becoming a member of the Hang Seng Index in November 2025.

  Other
  Source
• 2022Eli Lilly terminates sintilimab agreement after FDA rejection

  Eli Lilly ended its agreement with Innovent in December 2022 after the United States Food and Drug Administration rejected an application involving sintilimab.

  RegulationOther
  Source
• 2021Olverembatinib receives Chinese approval for chronic myeloid leukemia

  Olverembatinib, a tyrosine kinase inhibitor, received approval in China for defined patients with chronic myeloid leukemia, adding a small-molecule targeted therapy to Innovent’s portfolio.

  Product launch
  Source
• 2020Eli Lilly obtains rights outside China to sintilimab

  Eli Lilly agreed to pay an upfront amount and provide additional potential funding for rights to develop and commercialize sintilimab outside China.

  M&AOther
  Source
• 2019Innovent and Eli Lilly expand oncology collaboration

  The companies expanded their strategic collaboration to develop and commercialize additional oncology assets, reinforcing Innovent’s partnership-based development model.

  M&A
  Source
• 2018Innovent completes Hong Kong initial public offering

  Innovent became a publicly traded company on the Hong Kong Stock Exchange through an initial public offering that raised capital for research, development, manufacturing, and commercialization.

  Other
  Source
• 2018China approves Innovent’s sintilimab

  Sintilimab, an anti-PD-1 monoclonal antibody, received regulatory approval in China and became a central product in Innovent’s oncology portfolio.

  Product launchProduct generation
  Source
• 2018Innovent Biologics completes Hong Kong listing

  Innovent listed its shares on the Main Board of the Hong Kong Stock Exchange, providing financing for research, manufacturing, and commercial expansion.

  Other
  Source
• 2018China approves sintilimab for relapsed or refractory classical Hodgkin lymphoma

  Sintilimab, marketed as TYVYT and developed with Eli Lilly, became Innovent’s first major commercial oncology product after Chinese regulatory approval.

  Product launch
  Source
• 2015Innovent and Eli Lilly agree on cancer-drug development collaboration

  Innovent and Eli Lilly entered an agreement involving an upfront payment and the co-development of at least three experimental cancer medicines, with additional payments tied to development and commercial milestones.

  M&AOther
  Source

1. Innovent Biologics
2. Innovent Biologics official website
3. Olverembatinib receives Chinese approval for chronic myeloid leukemia
4. Innovent and Eli Lilly expand oncology collaboration
5. Innovent Biologics completes Hong Kong listing